Современные подходы к диагностике, стратификации риска и интервенционному лечению больных острым коронарным синдромом без подъема сегмента ST


Цитировать

Полный текст

Аннотация

В статье рассматриваются современные подходы к диагностике и определению индивидуального профиля риска у больных острым коронарным синдромом без подъема сегмента 8Т. Представлены основные принципы определения выбора той или иной стратегии лечения и временные интервалы для ее проведения. Изложены технические особенности выполнения интервенционного лечения в данной группе пациентов, обсужден выбор того или иного метода реваскуляризации миокарда.

Об авторах

Андрей Вячеславович Ардашев

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: avstaferov@mail.ru

заведующий отделением рентгенохирургических методов диагностики и лечения-2 ФГБУ ФНКЦ ФМБА России, доктор медицинских наук, профессор 

Россия, Москва, Ореховый бульвар. дом 28

Антон Валерьевич Стаферов

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: avstaferov@mail.ru

заведующий отделением рентгенохирургических методов диагностики и лечения-1 ФГБУ ФНКЦ ФМБА России, кандидат медицинских наук

Россия, Москва, Ореховый бульвар. дом 28

Алексей Васильевич Конев

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: konevalexv@mail.ru

заведующий отделением хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции ФТБУ ФНКЦФМБА России, кандидат медицинских наук

Россия, Москва, Ореховый бульвар. дом 28

Наталья Сергеевна Афонина

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: oms.fnkc@mail.ru

начальник отдела ОМС ФГБУ ФНКЦ ФМБА России, кандидат медицинских наук

Россия, Москва, Ореховый бульвар. дом 28

Наталья Ивановна Негрун

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: info@eco-vector.com

врач-кардиолог отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции

Россия, Москва, Ореховый бульвар. дом 28

Орыся Васильевна Химий

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: Orysya-himii@mail.ru

врач-кардиолог отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции

Россия, Москва, Ореховый бульвар. дом 28

Екатерина Геннадьевна Chelombitko

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Автор, ответственный за переписку.
Email: mauel3@rambler.ru

врач-кардиолог отделения хирургического лечения сложных нарушений ритма сердца и элекгрокардиостимуляции

Россия, Москва, Ореховый бульвар. дом 28

Список литературы

  1. Roffi М., Patrono С., Collet J.P. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015 Aug 29. pii:ehv320. Epub ahead of print.
  2. Mockel M, Searle J, Hamm C, et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 2015; 36: 369-376.
  3. Body R., Carley S., McDowell G., et. al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol 2011; 58:1332-1339.
  4. Bandstein N., Ljung R., Johansson M., et al. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014; 63:2569-2578.
  5. Than M, Cullen L, Reid CM, et al. A 2-hour diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet 2011;377:1077-1084.
  6. Than M., Cullen L., Aldous S., et al. 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J. Am Coll Cardiol 2012; 59:2091-2098.
  7. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol 2013; 62:1242-1249.
  8. Campeau L. Letter: grading of angina pectoris. Circulation 1976; 54:522-523.
  9. Canto J.G., Fincher C., Kiefe C.I., et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J. Cardiol 2002; 90:248- 253.
  10. Mackay M.H., Ratner PA, Johnson J.L., et al. Gender differences in symptoms of myocardial ischaemia. Eur Heart J 2011; 32:3107-3114.
  11. Rubini Gimenez M., Reiter M., Twerenbold R., et al. Sex specific chest pain characteristics in the early diagnosis of acute myocardial infarction. JAMA Intern Med 2014; 174:241-249.
  12. Persson A., Hartford M., Herlitz J., et al. Longterm prognostic value of mitral regurgitation in acute coronary syndromes. Heart 2010; 96:1803-1808.
  13. Grani C., Senn O, Bischof M., et al. Diagnostic performance of reproducible chest wall tenderness to rule out acute coronary syndrome in acute chest pain: a prospective diagnostic study. BMJ Open 2015; 5:e007442
  14. Devon HA, Rosenfeld A, Steffen AD, et al.
  15. Sensitivity, specificity, and sex differences in symptoms reported on the 13-item acute coronary syndrome checklist. J Am Heart Assoc 2014; 3:e000586
  16. Diercks D.B., Peacock W.F., Hiestand B.C., et al. Frequency and consequences of recording an electrocardiogram 10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). Am J Cardiol 2006; 97: 437-442.
  17. Steg P.G., James S.K., Atar D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569-2619.
  18. Savonitto S., Ardissino D., Granger C.B., et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707- 713.
  19. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33:2551-2567.
  20. Kaul P., Fu. Y., Chang WC., et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-НВ. PARAGON-A and GUSTO IIB Investigators. Platelet IIB/HIA antagonism for the reduction of acute global organization network. J Am Coll Cardiol 2001; 38:64-71.
  21. Mueller C., Neumann F.J., PerachW, et al. Prognostic value of the admission electrocardiogram in patients with unstable angina/non-ST-segment elevation myocardial infarction treated with very early revascularization. Am J Med 2004; 117:145-150.
  22. Тап N.S., Goodman S.G., Yan R.T., et al. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. Am HeartJ 2013; 166:290-297.
  23. Thygesen K., Mair J., Giannitsis Е., et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012; 33:2252-2257.
  24. Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014; 35:552-556.
  25. Thygesen K., Mair J., Mueller C., et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. Eur Heart J 2012; 33:2001-2006.
  26. Reichlin T., Twerenbold R., Reiter M., et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med 2012; 125:1205-1213, el201.
  27. Okamatsu K, Takano M, Sakai S, et al. Elevated troponin T levels and lesion characteristics in non- ST-elevation acute coronary syndromes. Circulation 2004; 109:465-470.
  28. Reichlin Т., Hochholzer W., Bassetti S., et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl J. Med 2009; 361:858- 867.
  29. Keller T., Zeller T., Peetz D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361:868-877.
  30. Keller T., Zeller T., Ojeda F., et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011; 306:2684-2693.
  31. Giannitsis Е, Becker M, Kurz K, et al. High- sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. ClinChem 2010; 56:642-650.
  32. Haaf P., Drexler B., Reichlin T., et al. Highsen- sitivity cardiac troponin in the distinction of acute myocardial infarctionfrom acute cardiac noncoronary artery disease. Circulation 2012; 126:31-40.
  33. Apple F.S. A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin Chern 2009; 55:1303-1306.
  34. RubiniGimenez M., Hoeller R., Reichlin T., et al. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardiol2013; 168:3896-3901.
  35. Reichlin T., Schindler C,. Drexler B., et al. One- hour ruleout and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012; 172:1211-1218.
  36. Reichlin T, Twerenbold R, Wild! K, et al. Prospective validation of a 1-hour algorithm to ruleout and rule-in acute myocardial infarction using a highsensitivity cardiac troponin T assay. CMAJ 2015; 187:E243-E252.
  37. Tong KL, Kaul S, Wang XQ, et al. Myocardial contrast echocardiography versus thrombolysis in myocardial infarction score in patients presenting to the emergency department with chest pain and a nondiagnostic electrocardiogram. J Am CollCardiol 2005; 46:920-927.
  38. Grenne B, Eek C, Sjoli B, et al. Acute coronary occlusion in non-ST-elevation acute coronary syndrome: outcome and early identification by strain echocardiography. Heart 2010; 96:1550-1556.
  39. Lancellotti P, Price S, Edvardsen T, et al. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2015;4:3-5.
  40. Fox KA, Fitzgerald G, Puymirat Е, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014; 4:e004425.
  41. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-842
  42. Mehran R, Pocock SJ, Nikolsky Е, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55:2556- 2566.
  43. Steg PG, Huber K, Andreotti F, et.al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32:1854-1864.
  44. Akkerhuis KM, Klootwijk PA, Lindeboom W, et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 2001; 22:1997-2006.
  45. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337:1648-1653.
  46. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335:1342-1349.
  47. Scirica BM, Morrow DA, Budaj A, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLINTIMI 36 (metabolic efficiency with ranola- zine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36) trial. J Am CollCardiol2009; 53:1411-1421.
  48. Zhelev Z, Hyde C, Youngman Е, et al. Diagnostic accuracy of single baseline measurement of Elecsys troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ 2015; 350:hl5.
  49. RubiniGimenez M, Twerenbold R, Jaeger C, et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. Am J Med 2015; 128:861-870.e4.
  50. Twerenbold R, Wildi K, Jaeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation 2015; 131:2041-2050.
  51. Weber M, Bazzino O, Navarro Estrada JL, et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J 2011; 162:81-88.
  52. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333:1091.
  53. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-ele- vation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AH A guidelines) bleeding score. Circulation 2009; 119:1873-1882.
  54. Abu-Assi Е, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2012; 1:222-231.
  55. Shah B.N., Balaji G., Alhajiri A, et al. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. Circ Cardiovasc Imaging 2013; 6:202-209.
  56. Nabi F., Chang S.M., Xu. J., et al. Assessing risk in acute chest pain: the value of stress myocardial perfusion imaging in patients admitted through the emergency department. J Nucl Cardiol 2012; 19:233-243.
  57. Nyman I., Wallentin L., Areskog M., et al. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC study group. Int J Cardiol 1993; 39:131-142.
  58. Amsterdam E.A., Kirk J.D., Diercks D.B., et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am CollCardiol 2002; 40:251-256.
  59. Hulten Е., Pickett C., Bittencourt M.S., et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized,controlled trials. J Am Coll Cardiol 2013; 61:880-892.
  60. Drew B.J., Califf R.M., Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation 2004; 110:2721-2746.
  61. Rahimi K, Watzlawek S, Thiele H, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J 2006; 27:1706-1711.
  62. Piccini JP, White JA, Mehta RH, et al. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation 2012; 126:41-49.
  63. Montalescot G., Bolognese L., Dudek D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.
  64. Kastrati A., Neumann FJ., Mehilli J., et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688-696.
  65. Mehta S.R., Granger C.B., Boden W.E., et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360:2165- 2175.
  66. Thiele H., Rach J., Klein N.,et al. Optimal timing of invasive angiography in stable non-ST-ele- vation myocardial infarction: the Leipzig immediate versus early and late Percutaneous coronary intervention triAl in NSTEMI (LIPSIA-NSTEMI trial). Eur Heart J 2012; 33:2035-2043.
  67. Ndrepepa G., Mehilli J., Schulz S.,et al. Patterns of presentation and outcomes of patients with acute coronary syndromes. Cardiology 2009; 113:198- 206.
  68. Kerensky R.A., Wade M., Deedwania P., et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trialan- giographic core laboratory. J Am Coli Cardiol 2002; 39:1456-1463.
  69. Ambrose J.A., Winters S.L., Stern A., et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5:609-616.
  70. Goldstein J.A., Demetriou D., Grines C.L., et al. Multiplecomplex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343:915-922.
  71. Libby P. Inflammation in atherosclerosis. Ar- terioscler Thromb Vase Biol 2012;32: 2045-2051.
  72. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47:C13-C18
  73. Vergallo R, Ren X, Yonetsu T, Kato K, et al. Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. Am Heart J 2014;167:59-67
  74. Cheruvu PK, Finn AV, Gardner C, et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol 2007;50: 940-949
  75. Shishehbor MH, Lauer MS, Singh IM, et al. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol 2007;49:849-854.
  76. Sgarbossa E.B., Birnbaum Y, Parrillo J.E. Electrocardiographic diagnosis of acute myocardial infarction: current concepts for the clinician. Am Heart J 2001; 141:507-517.
  77. Kurisu S., Inoue I., Kawagoe T, et al. Electrocardiographic features in patients with acute myocardial infarction associated with left main coronary artery occlusion. Heart 2004;90:1059-1060.
  78. de Winter R.J., Verouden NJ., Wellens HJ., Wilde А.А. A new ECG sign of proximal LAD occlusion. N Engl J Med 2008; 359:2071-2073.
  79. Tahvanainen M., Nikus K.C., Holmvang L., et al. Factors associated with failure to identify the culprit artery by the electrocardiogram in inferior ST-el- evation myocardial infarction. J Electrocardiol 2011; 44:495-501.
  80. Tanaka A., Shimada K., Tearney GJ, et al. Conformational change in coronary artery structure assessed by optical coherence tomography in patients with vasospastic angina. J Am Coll Cardiol 2011; 58:1608-1613.
  81. Kato M, Dote K, Sasaki S, et al. Presentations of acute coronary syndrome related tocoronary lesion morphologies as assessed by intravascular ultrasound and optical coherence tomography. Int J Cardiol 2013; 165:506-511.
  82. Pijls NH, Tanaka N, Fearon WE Functional assessment of coronary stenoses: can we live without it? Eur Heart J 2013; 34:1335-1344.
  83. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319-1325.
  84. O’Donoghue M, Boden WE, Braunwald Е, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST- segment elevation myocardial infarction: a meta-analysis. JAMA 2008; 300:71-80.
  85. Fox KA, Clayton TC, Damman P, et al. Longterm outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55:2435-2445.
  86. Noc M, Fajadet J, Lassen JF, et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent For Life (SFL) groups. EuroIntervention 2014; 10:31-37.
  87. Katritsis DG, Siontis GC, Kastrati A, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J 2011; 32:32-40.
  88. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non- ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med 2013; 158:261-270.
  89. Riezebos RK, Ronner Е, TerBals Е, et al. Immediate versus deferred coronary angioplasty in non- ST-segment elevation acute coronary syndromes. Heart 2009; 95:807-812.
  90. Montalescot G, Cayla G, Collet JP, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 2009;302:947-954.
  91. Sorajja P, Gersh BJ, Cox DA, et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2010;55:1416-1424.
  92. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation 2010; 122:1756-1776.
  93. De Ferrari GM, Fox KA, White JA, et al. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographicallyob- structive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care 2014;3:37-45.
  94. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
  95. Solomon MD, Go AS, Shilane D, et al. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2014; 63:2249-2257.
  96. Roe MT, Armstrong PW, Fox KA, et al. TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297-1309.
  97. James SK, Roe MT, Cannon CP, et al. Ticagre- lor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011; 342:d3527.
  98. Williams B, Menon M, Satran D, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Cathet Cardiovasc Interv 2010; 75:886- 891.
  99. Henry TD, Satran D, Hodges JS, et al. Longterm survival in patients with refractory angina. Eur Heart J 2013; 34:2683-2688.
  100. ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J 2013; 34:2949-3003.
  101. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308:777-787
  102. Sabate M, Cequier A, Iniguez A, et.al. Evero- limus-eluting stent versus bare-metal stent in ST-seg- ment elevation myocardial infarction (examination): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-1490.
  103. Valgimigli M, Tebaldi M, Borghesi M, et al. Two year outcomes after first- or seco nd-generation drug-eluting or bare-metal stent implantation in allcomer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study). JACC Cardiovasc Interv 2014;7:20-28.
  104. Lagerqvist B, Frobert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014; 371:1111-1120.
  105. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377:1409-1420.
  106. Rao SV, Hess CN, Barham B, et al. A registrybased randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv 2014; 7:857-867.
  107. Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multi centre trial. Lancet 2015;385:2465- 2476.
  108. Cannon CP, Weintraub WS, Demopoulos LA, et.al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ilb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879-1887.
  109. Fox KA, Poole-Wilson PA, Henderson RA, et al. Randomized Intervention Trial of unstable Angina I. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. Lancet 2002; 360:743-751.
  110. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 2000;356:9-16.
  111. Farooq V, Serruys PW, Bourantas CV, et al.
  112. Quantification of incomplete revascularization and its association with five-year mortality in the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013; 128:141-151.
  113. Genereux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (SYNergy between PCI with TAXus and cardiac surgery) score. J Am Coll Cardiol 2012;59:2165-2174.
  114. Ranasinghe I, Alprandi-Costa B, Chow V, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011;108:617-624.
  115. Martensson S, Gyrd-Hansen D, Prescott Е, et al. Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. BMJ Open 2014; 4:e004052.
  116. Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013; 145:1577-1583.
  117. Ben-Gal Y, Moses J W, Mehran R, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. JACC Cardiovasc Interv 2010; 3:1059-1067.
  118. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373:1190-1197.
  119. Mohr FW, Morice МС, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three- vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629-638.
  120. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367:2375-2384.
  121. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2014; 35:2541-2619.
  122. Palmerini T, Genereux P, Caixeta A, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. J Am Coll Cardiol 2011; 57:2389-2397.
  123. Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein Ilb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36:685-692.
  124. Holmes DR Jr., Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100:2067-2073.
  125. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med 1999; 131:47-59.
  126. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287-1296.
  127. Stefanini GG, Baber U, Windecker S, et al. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomized trials. Lancet 2013; 382:1879-1888.
  128. Kaiser C, Galatius S, Erne Petal. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363:2310-2319.
  129. Greenhalgh J, Hockenhull J, Rao N, et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 5:CD004587
  130. Kirtane AJ, Gupta A, Iyengar S, Moses JW, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119:3198-3206.
  131. Moses JW, Mehran R, Nikolsky Е, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am CollCardiol 2005; 45:1165- 1171.
  132. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coli Cardiol 2015; 65:805-815.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать
2. Рис. 1. «0/3» часовой алгоритм ведения пациентов с ОКСбпST с использованием высокочувствительных тропонинов [1].

Скачать (275KB)
Метаданные
3. Рис. 2. Выбор стратегии лечения и временного интервала оказания помощи пациентам с ОКСбпST в соответствии со стратификацией риска.

Скачать (299KB)
Метаданные

© Ардашев А.В., Стаферов А.В., Конев А.В., Афонина Н.С., Негрун Н.И., Химий О.В., Chelombitko Е.Г., 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах